Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
subjects who have been treated with HB110E 2mg or 4mg within 6 months prior to screening.
positive HBsAg at screening
serum HBV DNA level below 300copies/mL at screening
ALT level within 2 x ULN at screening
voluntarily provide the informed consent
participation in other study within 30 days of screening
subjects with severe allergic reaction or severe adverse event to HBsAg vaccine, or not suitable for HBsAg vaccine.
any other conditions that are considered inappropriate for the study by the investigator